"STC-15 is a first-in-class, oral small-molecule inhibitor of METTL3, an enzyme that methylates messenger RNA and plays a central role in cancer stem cell differentiation. It is the first RNA-modifying enzyme inhibitor ever to enter human clinical trials, having commenced its Phase 1 study in November 2022."
"Inhibiting METTL3 disrupts the process of adding a chemical tag called m6A to mRNA, which influences how cells read genetic instructions. This inhibition pushes cancer cells towards cycle arrest and programmed death."
"Sarcomas account for 1% of adult cancers and 15% of pediatric cancers. They are notoriously difficult to treat because they frequently lack the driver mutations or immunogenic features that make most solid tumors amenable to targeted therapy or immunotherapy."
STC-15, an oral small-molecule inhibitor of METTL3, is the first RNA-modifying enzyme inhibitor to enter human trials. Phase 1 results demonstrated durable tumor regression across various sarcoma subtypes. STORM Therapeutics raised $56 million in a Series C funding round, entirely from existing investors, to support the ongoing Phase 2 trial of STC-15. Sarcomas, which arise from bone or soft tissue, are challenging to treat due to their lack of driver mutations and immunogenic features, making METTL3 inhibition a promising therapeutic approach.
Read at TNW | Health-Tech
Unable to calculate read time
Collection
[
|
...
]